Blood
Blood
5 years ago

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Younes A, Matasar M, Kumar A, McCall SJ, Perales MA, Straus D, Horwitz SM, Ni A, Zelenetz AD, Moskowitz CH, Hamlin PA, Fox SY, Cadzin BR, Thoren KL, Yahalom J, Gavane S, Moskowitz AJ, Sauter C, Noy A, Schöder H, Palomba ML, Fleisher M, Portlock CS, Grewal R, Gerecitano J
Identification of prognostic factors for patients with relapsed or refractory (rel/ref) Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase II study of PET-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carboplatin, etoposide (augICE) we assessed clinical factors, quantitative PET assessments, and cytokines/chemokine values. Transplant-eligible patients with rel/ref HL received 2 (cohort 1) or 3 (cohort 2) cycles of weekly BV; PET-negative (Deauville ≤ 2) patients proceeded to autologous stem cell transplant (ASCT) while PET-positive patients received augICE before ASCT. Serum cytokine and chemokine levels were measured at baseline and after BV. Metabolic tumor volume (MTV) and total lesion glycolysis were measured at baseline, after BV and after augICE. 65 patients enrolled (45 cohort 1, 20 cohort 2); 49 (75%) achieved CR and 64 proceeded to ASCT. 3-year overall survival and EFS were 95% and 82%. Factors predictive for EFS by multivariate analysis were baseline MTV (bMTV) (p<0.001) and refractory disease (p=0.003). Low bMTV (<109.5cm3) and relapsed disease identified a favorable group (3-yr EFS 100%). For transplanted patients, bMTV and pre-ASCT PET were independently prognostic; 3-year EFS for pre-ASCT PET-positive patients with low bMTV was 86%. In this phase II study of PET-adapted therapy with BV and augICE for rel/ref HL, bMTV and refractory disease were independent prognostic factors for EFS. Furthermore, bMTV improved the predictive power of pre-ASCT PET. Future studies should optimize efficacy and tolerability of salvage therapy by stratifying patients according to risk factors such as bMTV.

Publisher URL: https://www.ncbi.nlm.nih.gov/pubmed/28874350

DOI: PubMed:28874350

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.